Literature DB >> 6833474

Selective recovery of oral Capnocytophaga spp. with sheep blood agar containing bacitracin and polymyxin B.

P A Mashimo, Y Yamamoto, M Nakamura, J Slots.   

Abstract

On the basis of in vitro susceptibility testing of antibiotics, dyes, and other antimicrobial agents, we developed and evaluated a medium, TBBP, for the selective isolation of oral Capnocytophaga spp. TBBP medium consists of 4% Trypticase soy agar (BBL Microbiology Systems, Cockeysville, Md.), 5% sheep blood, 0.1% yeast extract, 50 micrograms of bacitracin per ml, and 100 micrograms of polymyxin B per ml. A total of 34 Capnocytophaga stock cultures grew well on TBBP medium. Except for some streptococcal strains, TBBP medium inhibited growth of all test stock culture isolates of common oral gram-positive and gram-negative species. In a clinical study of 15 deep periodontal pockets, TBBP medium demonstrated Capnocytophaga recoverability that was similar to or higher than that shown by a nonselective blood agar medium. Typical Capnocytophaga colonial morphology enabled us to readily distinguish this organism from the few other bacteria which could grow on TBBP medium.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6833474      PMCID: PMC272606          DOI: 10.1128/jcm.17.2.187-191.1983

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Bacterial studies of the Papillon-Lefévre syndrome.

Authors:  M Newman; I Angel; H Karge; M Weiner; V Grinenko; L Schusterman
Journal:  J Dent Res       Date:  1977-05       Impact factor: 6.116

2.  Haemophili and related bacteria in the human oral cavity.

Authors:  M Kilian; C R Schiott
Journal:  Arch Oral Biol       Date:  1975-12       Impact factor: 2.633

3.  The predominant cultivable organisms in juvenile periodontitis.

Authors:  J Slots
Journal:  Scand J Dent Res       Date:  1976-01

4.  Increased selectivity of Mitis-Salivarius agar containing polymyxin.

Authors:  R F Fitzgerald; B O Adams
Journal:  J Clin Microbiol       Date:  1975-02       Impact factor: 5.948

5.  Septicemia due to Capnocytophaga (Bacteroides ocharaceus) in Hodgkin's disease.

Authors:  P C Appelbaum; J O Ballard; M E Eyster
Journal:  Ann Intern Med       Date:  1979-04       Impact factor: 25.391

6.  A selective medium for Streptococcus mutans.

Authors:  O G Gold; H V Jordan; J Van Houte
Journal:  Arch Oral Biol       Date:  1973-11       Impact factor: 2.633

7.  Antibacterial susceptibility of plaque bacteria.

Authors:  M G Newman; C Hulem; J Colgate; C Anselmo
Journal:  J Dent Res       Date:  1979-07       Impact factor: 6.116

8.  Studies of the microbiology of periodontosis.

Authors:  M G Newman; S S Socransky; E D Savitt; D A Propas; A Crawford
Journal:  J Periodontol       Date:  1976-07       Impact factor: 6.993

9.  New medium for isolation of Actinomyces viscosus and Actinomyces naeslundii from dental plaque.

Authors:  K S Kornman; W J Loesche
Journal:  J Clin Microbiol       Date:  1978-06       Impact factor: 5.948

10.  Differential medium for detecting dental plaque bacteria resembling Actinomyces viscosus and Actinomyces naeslundii.

Authors:  R P Ellen; I B Balcerzak-Raczkowski
Journal:  J Clin Microbiol       Date:  1975-10       Impact factor: 5.948

View more
  10 in total

1.  Genetic analysis of an ambler class A extended-spectrum beta-lactamase from Capnocytophaga ochracea.

Authors:  Anne Jolivet-Gougeon; Zohreh Tamanai-Shacoori; Laurent Desbordes; Nathalie Burggraeve; Michel Cormier; Martine Bonnaure-Mallet
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  In vitro susceptibility of Capnocytophaga species to 29 antimicrobial agents.

Authors:  J L Rummens; B Gordts; H W Van Landuyt
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

3.  Isolation of Capnocytophaga species with a new selective medium.

Authors:  J L Rummens; J M Fossepre; M De Gruyter; H Van de Vyver; L Neyt; H W Van Landuyt
Journal:  J Clin Microbiol       Date:  1985-09       Impact factor: 5.948

4.  In vitro susceptibilities of Capnocytophaga isolates to beta-lactam antibiotics and beta-lactamase inhibitors.

Authors:  A Jolivet-Gougeon; A Buffet; C Dupuy; J L Sixou; M Bonnaure-Mallet; S David; M Cormier
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

5.  Bacteriological study of periodontal lesions in two sisters with juvenile periodontitis and their mother.

Authors:  K Okuda; Y Naito; K Ohta; Y Fukumoto; Y Kimura; I Ishikawa; S Kinoshita; I Takazoe
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

6.  Potential role of microorganisms isolated from periodontal lesions in the pathogenesis of inflammatory bowel disease.

Authors:  T E Van Dyke; V R Dowell; S Offenbacher; W Snyder; T Hersh
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

7.  In vitro susceptibility of 96 Capnocytophaga strains, including a beta-lactamase producer, to new beta-lactam antibiotics and six quinolones.

Authors:  G Arlet; M J Sanson-Le Pors; I M Casin; M Ortenberg; Y Perol
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

8.  Capnocytophaga ochracea infection: two cases and a review of the published work.

Authors:  P M Hawkey; H Malnick; S A Glover; N Cook; J A Watts
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

9.  Lysozyme-mediated aggregation and lysis of the periodontal microorganism Capnocytophaga gingivalis 2010.

Authors:  V J Iacono; S M Zove; B L Grossbard; J J Pollock; D H Fine; L S Greene
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

10.  Prevalence of oropharyngeal beta-lactamase-producing Capnocytophaga spp. in pediatric oncology patients over a ten-year period.

Authors:  Anne Jolivet-Gougeon; Zohreh Tamanai-Shacoori; Laurent Desbordes; Virginie Gandemer; Jean-Louis Sixou; Nolwenn Morvan-Graveline; Michel Cormier; Martine Bonnaure-Mallet
Journal:  BMC Infect Dis       Date:  2005-05-09       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.